SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
SCHEDULE 13D
(Amendment No. 2)
Under the Securities Exchange Act of 1934
Medical Technology and Innovations, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
5846 2M100
(CUSIP Number)
Richard J. Emmerich
Global Capital Management, Inc.
601 Carlson Parkway
Suite 200
Minnetonka, Minnesota 55305
(612) 476-7200
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
November 26, 1997
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule
13G to report the acquisition which is the subject of this Schedule
13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4),
check the following box [ ].
(continued on following pages)
<PAGE>
CUSIP No. 5846 2M100 Schedule 13D (Amendment No. 2)
1) Name of Reporting Persons/S.S. or I.R.S. Identification Nos.
of Above Persons
Global Capital Management, Inc./FEIN 41-1625323
2) Check the Appropriate Box if a Member of a Group
(a) [ ]
(b) [ ]
3) SEC Use Only
4) Source of Funds
WC
5) Check Box if Disclosure of Legal Proceedings is Required
Pursuant to Item 2(d) or 2(e) [ ]
6) Citizenship or Place of Organization
Delaware
Number of Shares Beneficially Owned by Each Reporting Person
with:
(7) Sole Voting Power
535,367 (See Item 5)
(8) Shared Voting Power
0
(9) Sole Dispositive Power
535,367 (See Item 5)
(10) Shared Dispositive Power
0
11) Aggregate Amount Beneficially Owned by Each Reporting Person
535,367 (See Item 5)
12) Check Box if the Aggregate Amount in Row (11) Excludes
Certain Shares [ ]
13) Percent of Class Represented by Amount in Row (11)
3.3% (See Item 5)
14) Type of Reporting Person
CO
Page 2 of 4 Pages
<PAGE>
SCHEDULE 13D
AMENDMENT NO. 2
This Amendment No. 2 is being filed pursuant to Section
13(d) of the Securities Exchange Act of 1934 and the rules and
regulations promulgated thereunder. This Amendment No. 2 amends and
supplements the Statement on Schedule 13D, as amended by Amendment No.
1 thereto (the "Schedule 13D"), relating to the common stock, no par
value ("Common Stock"), of Medical Technology and Innovations, Inc., a
Florida corporation (the "Issuer"), previously filed by Global Capital
Management, Inc., a Delaware corporation ("Global"). Capitalized
terms used and not defined herein shall have the meanings set forth in
the Schedule 13D.
ITEM 4. PURPOSE OF TRANSACTION.
Item 4 is amended by adding the following:
The agreement in principle between Global Bermuda and Faisal
Finance (Switzerland) SA described in Amendment No. 1 to the Schedule
13D was not implemented.
Global Bermuda elected not to require compliance with its
Conversion Notice and the Issuer redeemed the 45 shares of Series A
Preferred Stock held by Global Bermuda at $3,800 per share. In
connection therewith, the Issuer agreed to reduce the exercise price
of the Warrant to $1.00 per share, and Global Bermuda and the Issuer
executed mutual releases. Global Bermuda received payment of the
redemption price on November 26, 1997.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
Items 5(a) and 5(c) are hereby amended to read as follows:
(a) As of the date of this Amendment No. 2, Global Capital
Management is the beneficial owner of an aggregate of
535,367 shares of Common Stock, consisting of the 260,138
shares of Common Stock held by Global Bermuda and the
275,229 shares of Common Stock underlying the Warrant. The
Issuer's Form 10-QSB for the quarter ended March 31, 1997
(which appears to be the Issuer's most recently available
filing with the Securities and Exchange Commission) stated
that as of that date there were 15,826,000 shares of Common
Stock outstanding. Based on that number of shares and
treating the shares of Common Stock underlying the Warrant
as also being outstanding, Global Capital Management would
be deemed to be the beneficial owner of 3.3% of the Issuer's
outstanding Common Stock.
Page 3 of 4 Pages
<PAGE>
(c) No transactions in Common Stock were effected by Global
Capital Management during the sixty (60) days prior to the
date of this Amendment.
Item 5 is amended by adding a subsection (e) as follows:
(e) Global Capital Management ceased to be the beneficial owner
of more than five percent of the Issuer's Common Stock on
November 26, 1997.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is
true, complete and correct.
Date: December 2, 1997 GLOBAL CAPITAL MANAGEMENT, INC.
By: /s/ John D. Brandenborg
-------------------------------
Name: John D. Brandenborg
Title: Vice-President
Page 4 of 4 Pages
